Bitcoin

The market's complete indifference to this medical trial underscores crypto's current decoupling from traditional risk assets - while biotech stocks might react to such news, Bitcoin's high dominance (62%) and 'flight to quality' behavior show crypto is now priced as a macro liquidity play. This reinforces that 2024's crypto narrative is dominated by US monetary policy, not sector-specific innovations, with macro signals overriding 90% of non-crypto news flow.

A clinical trial of CAR T cell therapy for multiple sclerosis was conducted at the University of Nebraska Medical Center with Jan Janisch-Hanzlik as the first patient.